CITIUS ONCOLOGY, INC. (CTOR)
Data as of , from SEC Form 4 filings.
See up to 3 months of CTOR. The 7-day demo opens the 1M and 3M ranges and puts CTOR on your watchlist.
Start 7-day demoLatest CTOR insider trades
About CITIUS ONCOLOGY, INC. (CTOR)
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
- CRANFORD, NJ
- 2024
- XNAS
CTOR Form 4 activity by transaction type, last 90 days
No Form 4 activity for CTOR in the last 90 days.
CTOR insider transactions (Form 4)
3141 Form 4 filings on record, the earliest from Dec 16, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Carol Webb - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Myron Z. Holubiak - Officer | Grant or award | Common Stock | 850,000 | $0.00 | - | |
| Myron Czuczman - Officer | Grant or award | Common Stock | 825,000 | $0.00 | - | |
 Jaime Bartushak - Officer | Grant or award | Common Stock | 825,000 | $0.00 | - | |
 Leonard L. Mazur - Officer | Grant or award | Common Stock | 1,700,000 | $0.00 | - | |
| Robert Joseph Smith - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Dennis M. McGrath - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Joel David Mayersohn - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
 Suren G. Dutia - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Eugene Myron Holuka - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Eugene Myron Holuka - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Joel David Mayersohn - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Carol Webb - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Dennis M. McGrath - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Jaime Bartushak - Officer | Grant or award | Common Stock | 825,000 | $0.00 | - | |
| Myron Z. Holubiak - Officer | Grant or award | Common Stock | 850,000 | $0.00 | - | |
| Robert Joseph Smith - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Suren G. Dutia - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Leonard L. Mazur - Officer | Grant or award | Common Stock | 1,700,000 | $0.00 | - | |
| Myron Czuczman - Officer | Grant or award | Common Stock | 825,000 | $0.00 | - | |
| Robert Joseph Smith - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Myron Czuczman - Officer | Grant or award | Common Stock | 825,000 | $0.00 | - | |
| Jaime Bartushak - Officer | Grant or award | Common Stock | 825,000 | $0.00 | - | |
| Eugene Myron Holuka - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Carol Webb - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Joel David Mayersohn - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Suren G. Dutia - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Leonard L. Mazur - Officer | Grant or award | Common Stock | 1,700,000 | $0.00 | - | |
| Dennis M. McGrath - Director | Grant or award | Common Stock | 300,000 | $0.00 | - | |
| Myron Z. Holubiak - Officer | Grant or award | Common Stock | 850,000 | $0.00 | - | |
| Myron Z. Holubiak - Officer | Grant or award | Common Stock | 100,000 | $0.00 | - |
CTOR insider trading FAQ
What is the latest insider trade for CTOR?
CITIUS ONCOLOGY, INC. (CTOR) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-12-22. The full record for CTOR runs to 41 Form 4 filings, the earliest from 2024-12-16. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CTOR stock?
No insider purchases of CTOR were filed in the last 90 days.
How many insiders are selling CTOR stock?
No insider sales of CTOR were filed in the last 90 days.
Where can I see CTOR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CTOR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Carol Webb view on EDGAR
- - Myron Z. Holubiak view on EDGAR
- - Myron Czuczman view on EDGAR
- - Jaime Bartushak view on EDGAR
- - Leonard L. Mazur view on EDGAR
- - Robert Joseph Smith view on EDGAR
- - Dennis M. McGrath view on EDGAR
- - Joel David Mayersohn view on EDGAR
- - Suren G. Dutia view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where CTOR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CTOR with a 7-day demo
- CTOR on your watchlist
- Every CTOR Form 4 filing on record
- Up to 3 months of CTOR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
